5 papers in the library · 115 citations · publishing 2020-2024
Br J Clin Pharmacol January 17, 2024 Hannah Thurgur, Michael T. Lynskey, Anne Katrin Schlag et al. 7 citations
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.
Psychopharmacology May 1, 2022 Sam Craft, Jason Ferris, Monica J Barratt et al. 19 citations
Synthetic cannabinoid receptor agonists (SCRAs) may be used as an alternative to natural cannabis; however, they may carry a greater risk of problematic use and withdrawal. This study aimed to characterise the withdrawal symptom profile of SCRAs and compare their profile of effect with high-potency herbal cannabis. Global Drug Survey data (2015 and 2016) were used to access a clinically...
Translational Psychiatry August 10, 2021 Diego Quattrone, Ulrich Reininghaus, A. Richards et al.
Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms...
Substance Abuse February 22, 2021 S. Kiburi, K. Molebatsi, Vuyokazi Ntlantsana et al.
Background Previous research has reported increased risk for psychosis among individuals who use cannabis during adolescence. We conducted a systematic review and meta-analysis to investigate the interaction between adolescent cannabis use and other factors in moderating risk for psychosis later in life. Method We searched four electronic databases in June 2020 for articles that assessed...
Psychological Medicine March 18, 2020 Diego Quattrone, Laura Ferraro, Giada Tripoli et al. 89 citations
Abstract Background Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder. However, the evidence is mixed on whether any pattern of cannabis use is associated with a particular symptomatology in first-episode psychosis (FEP) patients. Method We analysed data from 901 FEP patients and 1235 controls recruited across six countries, as part of...